Immune Design Corp. Company Profile (NASDAQ:IMDZ)

About Immune Design Corp. (NASDAQ:IMDZ)

Immune Design Corp. logoImmune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IMDZ
  • CUSIP: N/A
  • Web:
  • Market Cap: $133.22 million
  • Outstanding Shares: 25,619,000
Average Prices:
  • 50 Day Moving Avg: $9.81
  • 200 Day Moving Avg: $8.59
  • 52 Week Range: $4.50 - $13.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.22
  • P/E Growth: -0.48
Sales & Book Value:
  • Annual Revenue: $16.46 million
  • Price / Sales: 8.09
  • Book Value: $2.87 per share
  • Price / Book: 1.81
  • EBITDA: ($47,730,000.00)
  • Net Margins: -324.33%
  • Return on Equity: -59.14%
  • Return on Assets: -49.55%
  • Current Ratio: 5.21%
  • Quick Ratio: 5.17%
  • Average Volume: 263,598 shs.
  • Beta: 2.78
  • Short Ratio: 7.87

Frequently Asked Questions for Immune Design Corp. (NASDAQ:IMDZ)

What is Immune Design Corp.'s stock symbol?

Immune Design Corp. trades on the NASDAQ under the ticker symbol "IMDZ."

How were Immune Design Corp.'s earnings last quarter?

Immune Design Corp. (NASDAQ:IMDZ) released its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.11. The business earned $0.73 million during the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. View Immune Design Corp.'s Earnings History.

When will Immune Design Corp. make its next earnings announcement?

Immune Design Corp. is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Immune Design Corp..

Where is Immune Design Corp.'s stock going? Where will Immune Design Corp.'s stock price be in 2017?

4 equities research analysts have issued 12-month price objectives for Immune Design Corp.'s stock. Their predictions range from $10.00 to $20.00. On average, they anticipate Immune Design Corp.'s stock price to reach $16.00 in the next twelve months. View Analyst Ratings for Immune Design Corp..

What are analysts saying about Immune Design Corp. stock?

Here are some recent quotes from research analysts about Immune Design Corp. stock:

  • 1. According to Zacks Investment Research, "Immune Design’s primary candidates, CMB305 is being evaluated for soft tissue sarcoma and G100 for Merkel cell carcinoma , follicular non-Hodgkin Lymphoma and sarcoma. The company expects to provide data this year on both the lead product candidate from both monotherapy and combination studies to support their potential registration paths towards commercialization. We are positive on its strategic agreements with companies like Sanofi, Roche, and Merck, which not only validate its GLAAS platform, but also provide the company with funds in the form of collaboration and license revenues. The company’s shares have outperformed the Medical-Drugs industry year to date. Loss estimates have remained mostly stable lately ahead of the Q2 results. The company has a mixed record of earnings surprises in the recent quarters." (7/18/2017)
  • 2. Jefferies Group LLC analysts commented, "Though 2016 was relatively quiet, we believe the year of trial execution helped establish a foundation to build upon in 2017, with accumulating CMB305/ LV305 OS data and randomized '305 and '100 datasets potentially helping confirm the agents' promise and potential regulatory path. With data at AACR, ASCO, ESMO, and ASH this year, we see catalysts to draw greater attention to IMDZ and drive upside for shares; increasing tgt to $16. Financials: 4Q OpEx was $16.6M, consisting of $12.0M R&D vs. our $11.6M est and $4.4M G&A, vs. our $4.2M est. Their net loss was $14.5M compared to our $13.8M est. The company ended the quarter with $110.4M in cash, which includes $30.3M from follow-on financing. IMDZ believes their cash position should provide a runway until 2H18. Updated follow-up data for CMB305 and LV305 in soft tissue sarcoma (STS) suggests survival tracking well ahead of historical data." (3/8/2017)

Who are some of Immune Design Corp.'s key competitors?

Who are Immune Design Corp.'s key executives?

Immune Design Corp.'s management team includes the folowing people:

  • Edward E. Penhoet Ph., D., Independent Chairman of the Board
  • Carlos V. Paya M.D., Ph.D., President, Chief Executive Officer, Director
  • Stephen R. Brady J.D., Executive Vice President, Strategy & Finance
  • Sergey Yurasov M.D., Ph.D., Senior Vice President, Clinical Development, and Chief Medical Officer
  • Jan Henrik Ter Meule M.D., Chief Scientific Officer
  • Melanie Morrison, Vice President - Oncology Platform Leader
  • Heidi Petersen, Vice President - Regulatory Affairs
  • Wayne R. Gombotz Ph.D., Chief Development Officer
  • David Baltimore Ph.D., Independent Director
  • Franklin M. Berger, Independent Director

How do I buy Immune Design Corp. stock?

Shares of Immune Design Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immune Design Corp.'s stock price today?

One share of Immune Design Corp. stock can currently be purchased for approximately $5.20.

MarketBeat Community Rating for Immune Design Corp. (NASDAQ IMDZ)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  220
MarketBeat's community ratings are surveys of what our community members think about Immune Design Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Immune Design Corp. (NASDAQ:IMDZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $16.00 (207.69% upside)
Consensus Price Target History for Immune Design Corp. (NASDAQ:IMDZ)
Price Target History for Immune Design Corp. (NASDAQ:IMDZ)
Analysts' Ratings History for Immune Design Corp. (NASDAQ:IMDZ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Wells Fargo & CompanyDowngradeOutperform -> Market Perform$29.00 -> $10.00N/AView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$20.00LowView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingBuy$18.00MediumView Rating Details
6/6/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
6/10/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 10/24/2015 forward)


Earnings History for Immune Design Corp. (NASDAQ:IMDZ)
Earnings by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Earnings History by Quarter for Immune Design Corp. (NASDAQ IMDZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017($0.65)($0.54)$1.50 million$0.73 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.57)($0.57)$1.34 million$2.06 millionViewListenView Earnings Details
11/9/2016Q316($0.71)($0.60)$1.73 million$8.20 millionViewListenView Earnings Details
8/9/2016Q2($0.68)($0.71)$1.50 million$1.13 millionViewN/AView Earnings Details
5/10/2016Q1($0.62)($0.61)$0.85 million$1.86 millionViewListenView Earnings Details
3/10/2016Q4($0.54)($0.60)$1.06 million$1.10 millionViewListenView Earnings Details
11/12/2015Q315($0.39)($0.37)$4.10 million$4.70 millionViewListenView Earnings Details
8/12/2015Q215($0.47)($0.54)$1.40 million$1.78 millionViewListenView Earnings Details
5/14/2015Q115($0.64)($0.56)$1.30 million$1.90 millionViewListenView Earnings Details
3/31/2015Q4 2014($0.68)($0.78)$0.78 million$1.80 millionViewListenView Earnings Details
11/12/2014Q3 14($0.36)($0.55)$0.20 million$3.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Immune Design Corp. (NASDAQ:IMDZ)
2017 EPS Consensus Estimate: ($2.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.61)($0.55)($0.58)
Q2 20172($0.65)($0.60)($0.63)
Q3 20172($0.74)($0.64)($0.69)
Q4 20172($0.76)($0.66)($0.71)
(Data provided by Zacks Investment Research)


Dividend History for Immune Design Corp. (NASDAQ:IMDZ)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Immune Design Corp. (NASDAQ:IMDZ)
Insider Ownership Percentage: 20.70%
Institutional Ownership Percentage: 51.47%
Insider Trades by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Institutional Ownership by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Insider Trades by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/19/2017Leo GuthartMajor ShareholderBuy10,000$6.09$60,900.00View SEC Filing  
9/18/2017Leo GuthartMajor ShareholderBuy10,000$9.70$97,000.00View SEC Filing  
8/1/2017Wayne GombotzInsiderSell10,000$11.43$114,300.00View SEC Filing  
7/11/2017Lewis W ColemanDirectorBuy12,000$9.05$108,600.00View SEC Filing  
7/10/2017Lewis W ColemanDirectorBuy10,000$9.00$90,000.00View SEC Filing  
7/7/2017Lewis W ColemanDirectorBuy8,000$9.27$74,160.00View SEC Filing  
1/4/2017Carlos V PayaInsiderSell3,940$5.35$21,079.00View SEC Filing  
1/4/2017Stephen R BradyEVPSell1,642$5.35$8,784.70View SEC Filing  
12/22/2016Lewis W ColemanDirectorSell10,000$6.20$62,000.00View SEC Filing  
12/16/2016Franklin M BergerDirectorSell50,000$6.55$327,500.00View SEC Filing  
9/20/2016Group L P ColumnMajor ShareholderBuy800,000$6.25$5,000,000.00View SEC Filing  
9/20/2016Lewis W ColemanDirectorBuy40,000$6.25$250,000.00View SEC Filing  
7/15/2016Stephen R BradyEVPBuy1,500$6.84$10,260.00View SEC Filing  
11/23/2015Wayne GombotzinsiderSell5,000$20.00$100,000.00View SEC Filing  
9/14/2015Wayne GombotzinsiderSell5,000$16.19$80,950.00View SEC Filing  
8/25/2015Lewis W ColemanDirectorBuy3,000$14.50$43,500.00View SEC Filing  
5/12/2015Proquest Investments Iv, L.P.Major ShareholderSell177,607$21.60$3,836,311.20View SEC Filing  
4/24/2015Proquest Investments Iv, L.P.Major ShareholderSell82,892$26.81$2,222,334.52View SEC Filing  
4/21/2015Franklin M BergerDirectorBuy25,000$26.50$662,500.00View SEC Filing  
4/21/2015Proquest Investments Iv, L.P.Major ShareholderSell45,820$26.51$1,214,688.20View SEC Filing  
4/16/2015Proquest Investments Iv, L.P.Major ShareholderSell53,914$28.23$1,521,992.22View SEC Filing  
4/7/2015Proquest Investments Iv, L.P.Major ShareholderSell7,495$26.72$200,266.40View SEC Filing  
3/25/2015Proquest Investments Iv, L.P.Major ShareholderSell18,156$27.64$501,831.84View SEC Filing  
3/23/2015Proquest Investments Iv, L.P.Major ShareholderSell44,464$27.52$1,223,649.28View SEC Filing  
3/18/2015Proquest Investments Iv, L.P.Major ShareholderSell50,309$26.09$1,312,561.81View SEC Filing  
3/12/2015Proquest Investments Iv, L.P.Major ShareholderSell129,342$24.94$3,225,789.48View SEC Filing  
3/9/2015Proquest Investments Iv, L.P.Major ShareholderSell39,446$25.45$1,003,900.70View SEC Filing  
7/29/2014Alta Partners Viii, L.P.Major ShareholderBuy299,559$12.00$3,594,708.00View SEC Filing  
7/29/2014Franklin M BergerDirectorBuy50,000$12.00$600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Immune Design Corp. (NASDAQ:IMDZ)
Latest Headlines for Immune Design Corp. (NASDAQ:IMDZ)
Loading headlines, please wait.



Immune Design Corp. (IMDZ) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.